Clinical Trial Update: Efficacy of Switching to DTG/3TC in Virologically-suppressed Adults Currently on B/F/TAF [Phase 4]

View source ↗

Summary

Phase 4 trial assessing switching virologically suppressed adults from bictegravir/emtricitabine/tenofovir alafenamide to dolutegravir/lamivudine; results were …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)
• Dovato (dolutegravir/lamivudine)

Snippet

Sponsor: Charlotte-Paige Rolle, MD | Conditions: HIV I Infection | Phase 4 | Status: COMPLETED | Results posted: 2024-10-17